Peptides, Pain & Inflammation
BPC-157 · 15 mg injection
Investigational · Not FDA approved
BPC-157 Injections
Rx
BPC-157 is the most talked-about peptide in recovery, and the one most people buy without anyone ever asking about their medical history. Here a licensed clinician reviews your case first, and you get the real evidence picture instead of the forum version.
Starting at
$69
/ mo
What the evidence actually shows
BPC-157 is a synthetic 15-amino acid peptide studied mainly in animal models of tendon, muscle, and gut healing. It is not FDA approved, and the first randomized controlled trial in humans began enrolling in 2026. Your clinician will walk you through what that means for your situation.
HUMAN EVIDENCE
Fewer than 30 participants across three uncontrolled pilot studies.
CONTROLLED EFFICACY
No randomized controlled efficacy trial has reported results.
LONG-TERM SAFETY
Long-term human safety and human immunogenicity remain unknown.
Regulatory status
BPC-157 is not FDA approved and is not on the FDA section 503A Bulks List. In July 2026, FDA staff recommended that neither BPC-157 free base nor BPC-157 acetate be added. The advisory process does not itself create approval or a compounding pathway. BPC-157 is also prohibited in competitive sport under the World Anti-Doping Agency category covering non-approved substances, and detection methods have been published.
HUMAN AND PRECLINICAL EVIDENCE
What the research shows
The evidence is not all equal. Human observations and animal findings are separated below so they cannot be mistaken for the same level of support.
Human evidence · Chronic knee-pain series
A retrospective report included 12 patients. Seven reported relief lasting beyond six months after intra-articular injection. There was no comparator, randomization or standardized preparation, so the finding cannot establish efficacy.
Human evidence · Intravenous pilot
A published pilot described intravenous administration in two participants and reported no immediate abnormalities. Two participants cannot establish safety, and this route does not answer whether the marketed injection is effective.
Preclinical evidence · Injury and GI models
Rat studies report structural, biomechanical or functional outcomes in tendon, ligament, muscle, bone and gastrointestinal models. These findings support further study but are not evidence of benefit in patients.
WHAT THIS MEANS
What this means: the research supports testing BPC-157 in properly controlled human trials. It does not yet establish a patient benefit, a validated dose or a long-term safety profile. After thirty years of animal work, the first randomized controlled trial began enrolling in February 2026, with results expected in 2027. We will update this page either way.
What is BPC-157 Injections?
BPC-157 is the most talked-about peptide in recovery, and the one most people buy without anyone ever asking about their medical history. Here a licensed clinician reviews your case first, and you get the real evidence picture instead of the forum version.
BPC-157 is a commercially synthesized 15-amino acid peptide originally described as a fragment associated with gastric juice research. Most published work concerns cell and animal models. Its human pharmacokinetic profile remains critically undercharacterized.
PRECLINICAL EVIDENCE
Cell and animal studies have reported effects involving VEGFR2 and Akt-eNOS signaling, growth-hormone receptor expression, nitric-oxide modulation, fibroblast activity and collagen-related repair. These are proposed preclinical mechanisms and have not established patient benefit.
A plausible mechanism is not evidence of clinical benefit.
Safety limits and suitability
The available human evidence is too limited to establish a standard treatment pathway. These points are presented for medical review and informed discussion.
What is not known
No randomized controlled efficacy trial has reported results. Human absorption, distribution, metabolism and elimination remain incomplete. There is no validated standard formulation or dosing regimen, no long-term human safety dataset, and inadequate evidence about human immunogenicity or drug interactions.
Who should not use it
Published human studies have not established formal contraindications, because the trials required to establish them have not been done. The following cautions apply clinical judgement to the known mechanism and evidence: active or previous cancer, pregnancy or breastfeeding, people trying to conceive, athletes subject to anti-doping rules, undiagnosed pain or injury, and untreated or undiagnosed gastrointestinal disease.
When telehealth is not the right setting
An in-person or urgent assessment may be more appropriate for an acute injury that has not been examined, suspected tendon rupture or fracture, gastrointestinal bleeding, unexplained weight loss, difficulty swallowing, persistent vomiting, anemia, worsening or night pain, pain with fever, or suspected malignancy.
Monitoring and expectations
A clinician establishes the diagnosis and assesses suitability before any treatment decision. Because there is no approved indication, no validated monitoring protocol exists. An online evaluation does not guarantee that a clinician will prescribe treatment.
MEDICAL REVIEW
Dr. Reza Omid
MD
Content reviewed against primary medical and regulatory sources
Review date
Selected medical and regulatory references
Primary and regulatory sources used for the current draft. The final reference list remains under medical review.
Frequently asked questions
Start with a clinical evaluation
Diagnosis and suitability come before a product decision. Completing the intake does not guarantee that a clinician will prescribe treatment.